Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform
✍ Scribed by Nicole L.W. Van Hal; Guus A.M.S. Van Dongen; Ellen M.C. Rood-Knippels; Paul Van Der Valk; Gordon B. Snow; Ruud H. Brakenhoff
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- French
- Weight
- 827 KB
- Volume
- 68
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
At present, tumor-targeting with monoclonal antibodies ( M U ) is among the most promising novel adjuvant-therapy modalities for the treatment of patients with minimal residual disease of head-and-neck squamous-cell carcinoma (HNSCC For this purpose we developed MAb U36, recognizing a 2 d kDa antigen expressed on the outer cell surface of squamouscell carcinomas and their normal counterparts. Clinical radioimmunoscintigraphy (RIS) and biodistribution studies have shown that the MAb-U36-defined antigen is a suitable target molecule for antibody-based therapy of head-and-neck cancer. In the present study we further characterized the antigen by cDNA cloning. The cDNA was isolated by expression cloning in COS-7 cells. Sequence analysis and database searching revealed that the MAb-U36-defined antigen is identical to the squamous-cellspecific CD44 splice variant epican. The epitope recognized by